儿科生理药代动力学模型资格认定新进展:促进儿科临床研究的包容性与多样性
该研究系统评估了儿科生理药代动力学(P-PBPK)模型的预测准确性,纳入22篇文献中22种小分子化合物的预测与观测药代参数。结果显示大部分预测值在观测值的0.8-1.25倍范围内,支持P-PBPK模型用于儿科精准给药,尤其在不同年龄、种族和疾病状态的儿童中。
要点
- CYP3A4代谢药物预测准确性高,56/59个P/O比值在0.5-2.0倍内。
- 新生儿及经肾、非肾、复杂途径消除的药物预测也较可靠。
核心结论
- P-PBPK模型预测与观测药代参数比值多数在可接受范围内,支持其用于儿科精准给药。
研究设计与样本
- 系统检索并分析22篇涉及P-PBPK预测与对应观测药代数据(如AUC和清除率)的文献,涵盖22种小分子化合物。
主要发现
- 12种CYP3A4代谢化合物中56/59个平均P/O比值在0.5-2.0倍内;6种其他酶代谢化合物中22/25个在0.5-2.0倍内。
- 经肾、非肾、复杂途径及FMO3消除的化合物中29/31个平均P/O比值在0.67-1.5倍内,包括5个新生儿P/O比值中的4个。
关键数值与推荐
- 预测/观测(P/O)均值比值在0.8-1.25倍内视为高度一致,0.67-1.5倍内为可接受,2倍内为较宽范围。
临床怎么用
- P-PBPK模型可作为精准给药策略的组成部分,用于不同年龄、种族和疾病状态的儿科患者剂量调整。
- 模型资格认定是监管机构接受该方法的关键步骤,有助于推动儿科临床研究的包容性与多样性。
局限性
- 仅纳入22种小分子化合物,未涵盖生物大分子及更多代谢途径。
- 部分化合物P/O比值超出2倍范围,提示模型预测准确性因药物而异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Robust prediction of pharmacokinetics (PKs) in pediatric subjects of diverse ages, ethnicities, and morbidities is critical. Qualification of pediatric physiologically-based pharmacokinetic (P-PBPK) models is an essential step toward enabling precision dosing of these vulnerable groups. Twenty-two manuscripts involving P-PBPK predictions and corresponding observed PK data (e.g., area under the curve and clearance) for 22 small-molecule compounds metabolized by CYP (3A4, 1A2, and 2C9), UGT (1A9 and 2B7), FMO3, renal, non-renal, and complex routes were identified; ratios of mean predicted/observed (P/O) PK parameters were calculated. Seventy-eight of 115 mean predicted PK parameters were within 0.8 to 1.25-fold of observed data, 98 within 0.67 to 1.5-fold, 109 within 2-fold, and only 6 P/O ratios were outside of these bounds. A set of 12 CYP3A4-metabolized compounds and a set of 6 metabolized by other enzymes, CYP1A2 (1 compound), CYP2C9 (2 compounds), UGT1A9 (1 compound) and UGT2B7 (2 compounds) had 56 of 59 and 22 of 25 mean P/O ratios, respectively, that fell within the > 0.5 and < 2.0-fold boundaries. For compounds covering renal, non-renal, complex, and FM03 routes of elimination, 29 of 31 mean P/O ratios fell within the 0.67 to 1.5-fold bounds, including 4 of 5 P/O ratios from newborns. P-PBPK modeling and simulation is a strategic component of the complement of precision dosing methods and has a vital role to play in dose adjustment in vulnerable pediatric populations, such as those with disease or in different ethnic groups. Qualification of such models is an essential step toward acceptance of this methodology by regulators.
引用
- Small BG, Johnson TN, Rowland Yeo K, et al. Another Step Toward Qualification of Pediatric Physiologically Based Pharmacokinetic Models to Facilitate Inclusivity and Diversity in Pediatric Clinical Studies. Clin Pharmacol Ther. 2022. PMID: 36306419. doi:10.1002/cpt.2777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。